Sanofi licenses preclinical compounds to China's Zai Lab

Sanofi (Euronext:SAN; NYSE:SNY) granted newco Zai Laboratory Inc. (Shanghai, China) a worldwide license to develop, manufacture and commercialize two preclinical compounds to treat chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma and idiopathic pulmonary fibrosis (IPF). Sanofi will be eligible to receive undisclosed development and regulatory milestones, plus tiered sales royalties. ...